ID   NT-32
AC   CVCL_C4N8
DR   Wikidata; Q116050016
RX   PubMed=36269546;
CC   Doubling time: 5.35 days (PubMed=36269546).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Asn486_Pro490del (c.1457_1471del); ClinVar=VCV000666267; Zygosity=Unspecified (PubMed=36269546).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=36269546).
CC   Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.
DI   NCIt; C95582; Pancreatic large cell neuroendocrine carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   70Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 19-12-24; Version: 4
//
RX   PubMed=36269546; DOI=10.1007/s13402-022-00727-z; PMCID=PMC9747820;
RA   Viol F., Sipos B., Fahl M., Clauditz T.S., Amin T., Kriegs M.,
RA   Nieser M., Izbicki J.R., Huber S., Lohse A.W., Schrader J.;
RT   "Novel preclinical gastroenteropancreatic neuroendocrine neoplasia
RT   models demonstrate the feasibility of mutation-based targeted
RT   therapy.";
RL   Cell. Oncol. (Dordr.) 45:1401-1419(2022).
//